84900 Federal Register / Vol. 89, No. 206 / Thursday, October 24, 2024 / Notices 

Individuals who plan to attend inperson or view the virtual meeting and 

need special assistance or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The meeting 

can be accessed from the NIH Videocast 

at the following link: https://

videocast.nih.gov/. 

Name of Committee: Muscular Dystrophy 

Coordinating Committee. 

Date: November 22, 2024. 

Time: 9:00 a.m. to 4:00 p.m. ET. 

Agenda: The purpose of this meeting is to 

bring together committee members, 

representing government agencies, patient 

advocacy groups, other voluntary health 

organizations and people with lived 

experience to discuss topics of interest to the 

muscular dystrophy communities and 

renewal of the committee’s strategic plan, the 

Action Plan for the Muscular Dystrophies. 

The committee will discuss gaps and 

opportunities to better understand the 

muscular dystrophies, advance treatments 

and improve the lives of affected individuals. 

Registration: To register, please go to: 

https://web.cvent.com/event/ebf9b0d2-a61e400b-b8d9-5624d3d51f28/summary. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Room 1255/1265, Rockville, MD 

20852 (In-person and Virtual Meeting). 

Contact Person: Glen Nuckolls, Ph.D., 

National Institute of Neurological Disorders 

and Stroke (NINDS), NIH, 6001 Executive 

Blvd., Rockville, MD 20852, 301–496–5876, 

glen.nuckolls@nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors attending a meeting on 

campus or at an off-campus federal facility 

will be asked to show one form of 

identification (for example, a governmentissued photo ID, driver’s license, or passport) 

and to state the purpose of their visit. 

Information is also available on the 

Muscular Dystrophy Coordinating Committee 

website https://mdcc.nih.gov/, where an 

agenda and any addition information for the 

meeting will be posted when available. 

Dated: October 18, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–24642 Filed 10–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Clinical Trial 

Implementation Cooperative Agreement (U01 

Clinical Trial Required). 

Date: November 22, 2024. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G11, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Barry J. Margulies, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G11, Rockville, MD 

20892, (301) 761–7956, barry.margulies@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 21, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–24745 Filed 10–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

HHS Approval of Entities That Certify 

Medical Review Officers 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: This notice publishes a list of 

the Department of Health and Human 

Services (HHS) approved Medical 

Review Officers certification entities. 

The most recent HHS Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs (Mandatory 

Guidelines), effective on October 10, 

2023 (Oral Fluid) and February 1, 2024 

(Urine), address the role and 

qualifications of Medical Review 

Officers (MROs) and HHS approval of 

entities that certify MROs. 

DATES: HHS approval is effective 

October 24, 2024. 

FOR FURTHER INFORMATION CONTACT: 

Joshua Hunt, Pharm.D., MPH, LCDR, 

United States Public Health Service, 

Area/Regional Pharmacy Consultant, 

Substance Abuse and Mental Health 

Services Administration, 5600 Fishers 

Lane, Rockville, Maryland 20857; 

Telephone: (301) 642–9354; Email: 

Joshua.hunt@samhsa.hhs.gov. 

SUPPLEMENTARY INFORMATION: Subpart 

M—Medical Review Officer (MRO), 

Section 13.2 of the Mandatory 

Guidelines, ‘‘How are nationally 

recognized entities or subspecialty 

boards that certify MROs approved?’’ 

states as follows: ‘‘All nationally 

recognized entities or subspecialty 

boards which seek approval by the 

Secretary to certify physicians as MROs 

for Federal workplace drug testing 

programs must submit their 

qualifications, a sample examination, 

and other necessary supporting 

examination materials (e.g., answers, 

previous examination statistics or other 

background examination information, if 

requested). Approval will be based on 

an objective review of qualifications that 

include a copy of the MRO applicant 

application form, documentation that 

the continuing education courses are 

accredited by a professional 

organization, and the delivery method 

and content of the examination. Each 

approved MRO certification entity must 

resubmit their qualifications for 

approval every two years. The Secretary 

shall publish at least every two years a 

notice in the Federal Register listing 

those entities and subspecialty boards 

that have been approved.’’ 

HHS has completed its review of 

entities that certify MROs, in 

accordance with requests submitted by 

such entities to HHS. 

The HHS Secretary approves the 

following MRO certifying entities that 

offer MRO certification through 

examination: 

American Association of Medical 

Review Officers (AAMRO), 1506 E. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 206 / Thursday, October 24, 2024 / Notices 84901 

Franklin St., Suite 300, Chapel Hill, 

NC 27514, Phone: 1–800–489–1839, 

Email: bbrandon@aamro.com, 

Website: http://www.aamro.com/ 

Medical Review Officer Certification 

Council (MROCC), 3231 S. Halsted St, 

#167, Chicago, IL 60608, Phone: (847) 

631–0599, Email: mrocc@mrocc.org, 

Website: http://www.mrocc.org/ 

Dated: October 21, 2024. 

Xavier Becerra, 

Secretary, Department of Health and Human 

Services. 

[FR Doc. 2024–24735 Filed 10–23–24; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID FEMA–2024–0002] 

Final Flood Hazard Determinations 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: Notice. 

SUMMARY: Flood hazard determinations, 

which may include additions or 

modifications of Base Flood Elevations 

(BFEs), base flood depths, Special Flood 

Hazard Area (SFHA) boundaries or zone 

designations, or regulatory floodways on 

the Flood Insurance Rate Maps (FIRMs) 

and where applicable, in the supporting 

Flood Insurance Study (FIS) reports 

have been made final for the 

communities listed in the table below. 

The FIRM and FIS report are the basis 

of the floodplain management measures 

that a community is required either to 

adopt or to show evidence of having in 

effect in order to qualify or remain 

qualified for participation in the Federal 

Emergency Management Agency’s 

(FEMA’s) National Flood Insurance 

Program (NFIP). 

DATES: The date of March 11, 2025 has 

been established for the FIRM and, 

where applicable, the supporting FIS 

report showing the new or modified 

flood hazard information for each 

community. 

ADDRESSES: The FIRM, and if 

applicable, the FIS report containing the 

final flood hazard information for each 

community is available for inspection at 

the respective Community Map 

Repository address listed in the tables 

below and will be available online 

through the FEMA Map Service Center 

at https://msc.fema.gov by the date 

indicated above. 

FOR FURTHER INFORMATION CONTACT: Rick 

Sacbibit, Chief, Engineering Services 

Branch, Federal Insurance and 

Mitigation Administration, FEMA, 400 

C Street SW, Washington, DC 20472, 

(202) 646–7659, or (email) 

patrick.sacbibit@fema.dhs.gov; or visit 

the FEMA Mapping and Insurance 

eXchange (FMIX) online at https://

www.floodmaps.fema.gov/fhm/fmx_

main.html. 

SUPPLEMENTARY INFORMATION: The 

Federal Emergency Management Agency 

(FEMA) makes the final determinations 

listed below for the new or modified 

flood hazard information for each 

community listed. Notification of these 

changes has been published in 

newspapers of local circulation and 90 

days have elapsed since that 

publication. The Deputy Associate 

Administrator for Insurance and 

Mitigation has resolved any appeals 

resulting from this notification. 

This final notice is issued in 

accordance with section 110 of the 

Flood Disaster Protection Act of 1973, 

42 U.S.C. 4104, and 44 CFR part 67. 

FEMA has developed criteria for 

floodplain management in floodprone 

areas in accordance with 44 CFR part 

60. 

Interested lessees and owners of real 

property are encouraged to review the 

new or revised FIRM and FIS report 

available at the address cited below for 

each community or online through the 

FEMA Map Service Center at https://

msc.fema.gov. 

The flood hazard determinations are 

made final in the watersheds and/or 

communities listed in the table below. 

(Catalog of Federal Domestic Assistance No. 

97.022, ‘‘Flood Insurance.’’) 

Nicholas A. Shufro, 

Assistant Administrator (Acting) for Risk 

Management, Federal Emergency 

Management Agency, Department of 

Homeland Security. 

Community Community map repository address 

Itasca County, Minnesota and Incorporated Areas 

Docket No.: FEMA–B–2364 

City of Bigfork ........................................................................................... City Hall, 200 Main Avenue, Bigfork, MN 56628. 

City of Bovey ............................................................................................ City Hall, 402 2nd Street, Bovey, MN 55709. 

City of Cohasset ....................................................................................... City Hall, 305 Northwest 1st Avenue, Cohasset, MN 55721. 

City of Coleraine ....................................................................................... City Hall, 302 Roosevelt Street, Coleraine, MN 55722. 

City of Deer River ..................................................................................... City Hall, 60 2nd Street SE, Deer River, MN 56636. 

City of Grand Rapids ................................................................................ City Hall, 420 North Pokegama Avenue, Grand Rapids, MN 55744. 

City of Keewatin ....................................................................................... City Hall, 127 West 3rd Avenue, Keewatin, MN 55753. 

City of LaPrairie ........................................................................................ LaPrairie City Hall, 15 Park Drive, Grand Rapids, MN 55744. 

City of Taconite ........................................................................................ Community Building, 26 Haynes Street, Taconite, MN 55786. 

City of Warba ............................................................................................ City Hall, 130 South 2nd Avenue, Warba, MN 55793. 

City of Zemple .......................................................................................... Zemple City Hall, 606 County Road 139, Deer River, MN 56636. 

Leech Lake Band of Ojibwe ..................................................................... Leech Lake Band of Ojibwe Tribal Office, 190 Sailstar Drive Northwest, 

Cass Lake, MN 56633. 

Unincorporated Areas of Itasca County ................................................... Itasca County Courthouse, Department of Environmental Services, 123 

Northeast 4th Street, Grand Rapids MN 55744. 

Carroll County, Mississippi and Incorporated Areas 

Docket No.: FEMA–B–2247 

Unincorporated Areas of Carroll County .................................................. Carroll County Courthouse, 600 Lexington Street, Carrollton, Mississippi 38917. 


lotter on DSK11XQN23PROD with NOTICES1